B-cell differentiation antigen CD72 (CD72)

B-cell differentiation antigen CD72 (CD72) is a C-type lectin transmembrane co-receptor primarily expressed on B lymphocytes from early development through mature stages (excluding plasma cells)[1][2][3][4][5][6]. It acts as both a positive and negative regulator of B cell signaling, modulating activation thresholds and B cell fate by integrating signals from the B cell receptor (BCR) and other coreceptors[1][2][3][4][6]. CD72 recognizes self-antigen ligands such as the Sm/ribonucleoprotein (RNP) and, upon ligand binding or coligation with the BCR, recruits the tyrosine phosphatase SHP-1 to inhibit BCR-induced activation[5][6]. CD72 also binds CD100 (semaphorin 4D), further regulating B cell responses[2][3]. Genetic or functional defects in CD72 are implicated in autoimmune disorders such as lupus and can affect B cell proliferation and tolerance[3][5]. No approved drugs directly targeting CD72 are currently known, but its receptor activity and immune regulatory roles make it a candidate for therapeutic intervention in immune-mediated diseases[2][3][5].

Other names

LYB2Lyb-2CD72 antigenB-cell differentiation antigen CD72CD72b

Drugs could antagonize or agonize CD72 to modulate B-cell activity or BCR signaling (no specific drugs reported in search)